A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
SAGE Publications
2017
|
| _version_ | 1797081178413465600 |
|---|---|
| author | Davies, B Smith, J Rikabi, S Wartolowska, K Morrey, M French, A Maclaren, R Williams, D Bure, K Pinedo-Villanueva, R Mathur, A Birchall, M Snyder, E Atala, A Reeve, B Brindley, D |
| author_facet | Davies, B Smith, J Rikabi, S Wartolowska, K Morrey, M French, A Maclaren, R Williams, D Bure, K Pinedo-Villanueva, R Mathur, A Birchall, M Snyder, E Atala, A Reeve, B Brindley, D |
| author_sort | Davies, B |
| collection | OXFORD |
| description | Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments. |
| first_indexed | 2024-03-07T01:10:53Z |
| format | Journal article |
| id | oxford-uuid:8cf529c3-a948-4bbb-a3a1-799bf66e9815 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:10:53Z |
| publishDate | 2017 |
| publisher | SAGE Publications |
| record_format | dspace |
| spelling | oxford-uuid:8cf529c3-a948-4bbb-a3a1-799bf66e98152022-03-26T22:48:05ZA quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapiesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8cf529c3-a948-4bbb-a3a1-799bf66e9815Symplectic Elements at OxfordSAGE Publications2017Davies, BSmith, JRikabi, SWartolowska, KMorrey, MFrench, AMaclaren, RWilliams, DBure, KPinedo-Villanueva, RMathur, ABirchall, MSnyder, EAtala, AReeve, BBrindley, DCellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments. |
| spellingShingle | Davies, B Smith, J Rikabi, S Wartolowska, K Morrey, M French, A Maclaren, R Williams, D Bure, K Pinedo-Villanueva, R Mathur, A Birchall, M Snyder, E Atala, A Reeve, B Brindley, D A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title | A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title_full | A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title_fullStr | A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title_full_unstemmed | A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title_short | A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies |
| title_sort | quantitative multi national and multi stakeholder assessment of barriers to the adoption of cell therapies |
| work_keys_str_mv | AT daviesb aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT smithj aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT rikabis aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT wartolowskak aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT morreym aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT frencha aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT maclarenr aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT williamsd aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT burek aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT pinedovillanuevar aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT mathura aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT birchallm aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT snydere aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT atalaa aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT reeveb aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT brindleyd aquantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT daviesb quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT smithj quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT rikabis quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT wartolowskak quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT morreym quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT frencha quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT maclarenr quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT williamsd quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT burek quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT pinedovillanuevar quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT mathura quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT birchallm quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT snydere quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT atalaa quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT reeveb quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies AT brindleyd quantitativemultinationalandmultistakeholderassessmentofbarrierstotheadoptionofcelltherapies |